メニュー 戻るLS49 Introduction for DIA Japan Community

19th DIA Japan Annual Meeting 2022

New “Quest for the future”~Moving Creativity and Innovation Forward in “New Normal”~

価格は消費税抜きとなっております。

LS49 Introduction for DIA Japan Community

Session Chair(s)

Kazuhiko Ishida, MSc, RPh

Kazuhiko Ishida, MSc, RPh

  • Director, Pharmacovigilance
  • Astellas Pharma Inc., Japan

Speaker(s)

Tomohiko Takahashi

Tomohiko Takahashi

  • Associate Manager, Headquarters of Clinical Development
  • Otsuka Pharmaceutical Co., Ltd., Japan
So Miyoshi

So Miyoshi

  • Head of Clinical Pharmacology
  • Japan
Yoshiyuki Sugimoto

Yoshiyuki Sugimoto

  • Medical Manager
  • Sanofi K.K., Japan
Keiko Katsui, PhD

Keiko Katsui, PhD

  • Deputy Director / AMED Program Officer, Divison of Research Integrity, Social Co
  • Japan Agency for Medical Research and Development (AMED), Japan
Noriaki Nagao, MPharm, PMP

Noriaki Nagao, MPharm, PMP

  • Clinical Development Dept. Pharmaceutical Division
  • Japan
Kanji Hirai, RPh

Kanji Hirai, RPh

  • Director, Regulatory Policy & Intelligence, Regulatory Affair Area, Japan Dvlpmt
  • MSD, Japan
Taro Amagasaki, PhD

Taro Amagasaki, PhD

  • Head, Analytics Japan
  • Novartis Pharma K.K., Japan
Kotone Matsuyama, RPh

Kotone Matsuyama, RPh

  • Professor, Department of Health Policy and Management
  • Nippon Medical School, Japan